EUVIMEDAtrasti EUVIMED
Open access · CC BY 4.0

Translational tumor control probability modeling for NSCLC: A two‐dimensional maximum‐likelihood framework

Ryoichi Hinoto, Takeji Sakae, Kenta Takada, Takahisa Eriguchi, Masashi Mizumoto, Atsuya Takeda, Hideyuki Sakurai

Medical Physics · 2026-08 · 53 (8)

DOI: 10.1002/mp.70619 ↗

At a glance

Journal article in Medical Physics, published online on 2026-07-31. Written by Ryoichi Hinoto and 6 co-authors. Institution: Department of Radiation Oncology, Saitama Red Cross Hospital, Saitama, Saitama, Japan. Major MEDLINE topics: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Models, Biological, Translational Research, Biomedical. 51 references. The full text is freely available (open access, CC BY 4.0).

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Background

Tumor control probability (TCP) modeling for early‐stage non‐small cell lung cancer (NSCLC) is usually performed by one‐dimensional (1D) fitting that assumes error‐free dose and assigns all uncertainty to the local control (LC) axis. Neglecting dose‐axis uncertainties leads to a classical errors‐in‐variables (EIV) problem that can bias both the dose required for 50% TCP () and curve steepness. Furthermore, the mechanistic origins of TCP steepness remain incompletely characterized, limiting the translational link between cellular radiobiology and clinical dose–response.

Purpose

To develop a mechanistic TCP framework that (i) mitigates EIV bias by explicitly modeling uncertainties in both dose and LC, (ii) decomposes TCP steepness into contributions from clonogenic heterogeneity and inter‐patient radiosensitivity, and (iii) validates the translational consistency.

Methods

Cell‐survival data from A549 NSCLC cells were fitted with three radiobiological models—saturable repair and repairability (SRR), universal survival curve (USC), and linear–quadratic (LQ)—using maximum‐likelihood estimation. Clinical TCP modeling used 34 early‐stage NSCLC studies (41 data points, 3‐year LC). Prescriptions were converted to EQD2 using each model's formalism, and TCP curves were fitted by a two‐dimensional (2D) maximum‐likelihood framework. The LC‐axis uncertainty was constructed from binomial sampling uncertainty and an intrinsic scatter, the latter co‐estimated with the effective dose‐axis uncertainty. TCP steepness was measured by the inter‐patient variability of the TCP exponent and decomposed into clonogenic heterogeneity (, from reported tumor volumes) and inter‐patient radiosensitivity variability ().

Results

In cell‐survival fitting, the SRR and USC models accurately reproduced A549 survival (AIC = and 0.21); the LQ model achieved the lowest AIC () but only by inflating to 31.1 Gy. In clinical fitting, the SRR, USC, and LQ models yielded = 57.1, 51.6, and 50.2 Gy EQD2 and = 81.4, 71.8, and 60.5 Gy. The effective dose‐axis uncertainty (16.6%, 16.9%, and 10.5%) exceeded the mean relative LC‐axis uncertainty (5.0%, 5.0%, and 5.8%), supporting the need for a 2D framework. Variance decomposition revealed that clonogenic heterogeneity contributed only 3%–15% of , while inter‐patient radiosensitivity dominated (85%–97%); = 0.057–0.120 remained within the CLARIFi‐derived inter‐cell‐line bound of 0.255 (across 41 NSCLC cell lines). Fitted for the SRR and USC models implied mean tumor diameters of 2.6 and 3.2 cm, both falling within approximately one standard deviation of the clinical reference cm; the LQ‐model substantially overestimated the diameter (6.0 cm).

Conclusions

The proposed 2D maximum‐likelihood framework mitigates EIV bias and links clinical TCP to mechanistic cell‐survival models. In early‐stage NSCLC, inter‐patient radiosensitivity dominates TCP steepness while clonogenic cell‐number variability contributes negligibly. This framework provides a robust basis for future TCP modeling and dose‐prescription studies.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsModels, BiologicalTranslational Research, BiomedicalHumansProbabilityLikelihood FunctionsCell SurvivalA549 CellsRadiation Tolerance

Author keywords

errors‐in‐variablesmaximum likelihood modelingnon‐small cell lung cancerradiobiological modelingtumor control probability

Authors and institutions

  • Department of Radiation Oncology, Saitama Red Cross Hospital, Saitama, Saitama, Japan.
  • Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
  • Proton Medical Research Center, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan.
  • Graduate School of Radiological Technology, Gunma Prefectural College of Health Sciences, Maebashi, Gunma, Japan.
  • Department of Radiology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.

Cite

APA

Hinoto, R., Sakae, T., Takada, K., Eriguchi, T., Mizumoto, M., Takeda, A., & Sakurai, H. (2026). Translational tumor control probability modeling for NSCLC: A two‐dimensional maximum‐likelihood framework. Medical Physics, 53(8). https://doi.org/10.1002/mp.70619

Vancouver

Hinoto R, Sakae T, Takada K, Eriguchi T, Mizumoto M, Takeda A, et al. Translational tumor control probability modeling for NSCLC: A two‐dimensional maximum‐likelihood framework. Medical Physics. 2026;53(8). doi:10.1002/mp.70619

BibTeX
@article{Hinoto2026,
  author = {Hinoto, Ryoichi and Sakae, Takeji and Takada, Kenta and Eriguchi, Takahisa and Mizumoto, Masashi and Takeda, Atsuya and Sakurai, Hideyuki},
  title = {Translational tumor control probability modeling for NSCLC: A two‐dimensional maximum‐likelihood framework},
  journal = {Medical Physics},
  year = {2026},
  volume = {53},
  number = {8},
  doi = {10.1002/mp.70619}
}
Start for free →